Cargando…

Selective Inhibition of Liver Cancer Cells Using Venom Peptide

Increasingly cancer is being viewed as a channelopathy because the passage of ions via ion channels and transporters mediate the regulation of tumor cell survival, death, and motility. As a result, a potential targeted therapy for cancer is to use venom peptides that are selective for ion channels a...

Descripción completa

Detalles Bibliográficos
Autores principales: Anand, Prachi, Filipenko, Petr, Huaman, Jeannette, Lyudmer, Michael, Hossain, Marouf, Santamaria, Carolina, Huang, Kelly, Ogunwobi, Olorunseun O., Holford, Mandë
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6835663/
https://www.ncbi.nlm.nih.gov/pubmed/31627357
http://dx.doi.org/10.3390/md17100587
_version_ 1783466725678776320
author Anand, Prachi
Filipenko, Petr
Huaman, Jeannette
Lyudmer, Michael
Hossain, Marouf
Santamaria, Carolina
Huang, Kelly
Ogunwobi, Olorunseun O.
Holford, Mandë
author_facet Anand, Prachi
Filipenko, Petr
Huaman, Jeannette
Lyudmer, Michael
Hossain, Marouf
Santamaria, Carolina
Huang, Kelly
Ogunwobi, Olorunseun O.
Holford, Mandë
author_sort Anand, Prachi
collection PubMed
description Increasingly cancer is being viewed as a channelopathy because the passage of ions via ion channels and transporters mediate the regulation of tumor cell survival, death, and motility. As a result, a potential targeted therapy for cancer is to use venom peptides that are selective for ion channels and transporters overexpressed in tumor cells. Here we describe the selectivity and mechanism of action of terebrid snail venom peptide, Tv1, for treating the most common type of liver cancer, hepatocellular carcinoma (HCC). Tv1 inhibited the proliferation of murine HCC cells and significantly reduced tumor size in Tv1-treated syngeneic tumor-bearing mice. Tv1’s mechanism of action involves binding to overexpressed transient receptor potential (TRP) channels leading to calcium dependent apoptosis resulting from down-regulation of cyclooxygenase-2 (COX-2). Our findings demonstrate the importance of modulating ion channels and the unique potential of venom peptides as tumor specific ligands in the quest for targeted cancer therapies.
format Online
Article
Text
id pubmed-6835663
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-68356632019-11-25 Selective Inhibition of Liver Cancer Cells Using Venom Peptide Anand, Prachi Filipenko, Petr Huaman, Jeannette Lyudmer, Michael Hossain, Marouf Santamaria, Carolina Huang, Kelly Ogunwobi, Olorunseun O. Holford, Mandë Mar Drugs Article Increasingly cancer is being viewed as a channelopathy because the passage of ions via ion channels and transporters mediate the regulation of tumor cell survival, death, and motility. As a result, a potential targeted therapy for cancer is to use venom peptides that are selective for ion channels and transporters overexpressed in tumor cells. Here we describe the selectivity and mechanism of action of terebrid snail venom peptide, Tv1, for treating the most common type of liver cancer, hepatocellular carcinoma (HCC). Tv1 inhibited the proliferation of murine HCC cells and significantly reduced tumor size in Tv1-treated syngeneic tumor-bearing mice. Tv1’s mechanism of action involves binding to overexpressed transient receptor potential (TRP) channels leading to calcium dependent apoptosis resulting from down-regulation of cyclooxygenase-2 (COX-2). Our findings demonstrate the importance of modulating ion channels and the unique potential of venom peptides as tumor specific ligands in the quest for targeted cancer therapies. MDPI 2019-10-17 /pmc/articles/PMC6835663/ /pubmed/31627357 http://dx.doi.org/10.3390/md17100587 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Anand, Prachi
Filipenko, Petr
Huaman, Jeannette
Lyudmer, Michael
Hossain, Marouf
Santamaria, Carolina
Huang, Kelly
Ogunwobi, Olorunseun O.
Holford, Mandë
Selective Inhibition of Liver Cancer Cells Using Venom Peptide
title Selective Inhibition of Liver Cancer Cells Using Venom Peptide
title_full Selective Inhibition of Liver Cancer Cells Using Venom Peptide
title_fullStr Selective Inhibition of Liver Cancer Cells Using Venom Peptide
title_full_unstemmed Selective Inhibition of Liver Cancer Cells Using Venom Peptide
title_short Selective Inhibition of Liver Cancer Cells Using Venom Peptide
title_sort selective inhibition of liver cancer cells using venom peptide
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6835663/
https://www.ncbi.nlm.nih.gov/pubmed/31627357
http://dx.doi.org/10.3390/md17100587
work_keys_str_mv AT anandprachi selectiveinhibitionoflivercancercellsusingvenompeptide
AT filipenkopetr selectiveinhibitionoflivercancercellsusingvenompeptide
AT huamanjeannette selectiveinhibitionoflivercancercellsusingvenompeptide
AT lyudmermichael selectiveinhibitionoflivercancercellsusingvenompeptide
AT hossainmarouf selectiveinhibitionoflivercancercellsusingvenompeptide
AT santamariacarolina selectiveinhibitionoflivercancercellsusingvenompeptide
AT huangkelly selectiveinhibitionoflivercancercellsusingvenompeptide
AT ogunwobiolorunseuno selectiveinhibitionoflivercancercellsusingvenompeptide
AT holfordmande selectiveinhibitionoflivercancercellsusingvenompeptide